vs
Side-by-side financial comparison of EVERSPIN TECHNOLOGIES INC. (MRAM) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $14.9M, roughly 1.4× EVERSPIN TECHNOLOGIES INC.). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -84.4%, a 82.4% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs -65.2%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs 6.4%).
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
MRAM vs TRDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.9M | $20.6M |
| Net Profit | $-296.0K | $-17.3M |
| Gross Margin | 52.7% | — |
| Operating Margin | 29.0% | -106.0% |
| Net Margin | -2.0% | -84.4% |
| Revenue YoY | 13.2% | -65.2% |
| Net Profit YoY | — | -173.8% |
| EPS (diluted) | $-0.01 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.9M | — | ||
| Q4 25 | $14.8M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $13.2M | — | ||
| Q1 25 | $13.1M | $20.6M | ||
| Q4 24 | $13.2M | $37.4M | ||
| Q3 24 | $12.1M | $19.6M | ||
| Q2 24 | $10.6M | $94.7M |
| Q1 26 | $-296.0K | — | ||
| Q4 25 | $1.2M | — | ||
| Q3 25 | $54.0K | — | ||
| Q2 25 | $-670.0K | — | ||
| Q1 25 | $-1.2M | $-17.3M | ||
| Q4 24 | $1.2M | $1.1M | ||
| Q3 24 | $2.3M | $-14.0M | ||
| Q2 24 | $-2.5M | $55.0M |
| Q1 26 | 52.7% | — | ||
| Q4 25 | 50.8% | — | ||
| Q3 25 | 51.3% | — | ||
| Q2 25 | 51.3% | — | ||
| Q1 25 | 51.4% | — | ||
| Q4 24 | 51.3% | — | ||
| Q3 24 | 49.2% | — | ||
| Q2 24 | 49.0% | — |
| Q1 26 | 29.0% | — | ||
| Q4 25 | -7.2% | — | ||
| Q3 25 | -11.0% | — | ||
| Q2 25 | -14.9% | — | ||
| Q1 25 | -14.7% | -106.0% | ||
| Q4 24 | -11.8% | -15.7% | ||
| Q3 24 | -17.5% | -110.7% | ||
| Q2 24 | -26.5% | 56.4% |
| Q1 26 | -2.0% | — | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | -5.1% | — | ||
| Q1 25 | -8.9% | -84.4% | ||
| Q4 24 | 9.2% | 3.0% | ||
| Q3 24 | 18.8% | -71.7% | ||
| Q2 24 | -23.5% | 58.1% |
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $-0.05 | $-0.42 | ||
| Q4 24 | $0.07 | $-0.20 | ||
| Q3 24 | $0.10 | $-0.35 | ||
| Q2 24 | $-0.12 | $1.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.5M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $70.2M | $417.3M |
| Total Assets | $83.2M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.5M | — | ||
| Q4 25 | $44.5M | — | ||
| Q3 25 | $45.3M | — | ||
| Q2 25 | $45.0M | — | ||
| Q1 25 | $42.2M | $67.8M | ||
| Q4 24 | $42.1M | $101.2M | ||
| Q3 24 | $39.6M | $78.0M | ||
| Q2 24 | $36.8M | $185.3M |
| Q1 26 | $70.2M | — | ||
| Q4 25 | $68.9M | — | ||
| Q3 25 | $65.8M | — | ||
| Q2 25 | $64.1M | — | ||
| Q1 25 | $63.0M | $417.3M | ||
| Q4 24 | $62.6M | $428.7M | ||
| Q3 24 | $59.3M | $422.4M | ||
| Q2 24 | $55.4M | $429.9M |
| Q1 26 | $83.2M | — | ||
| Q4 25 | $84.6M | — | ||
| Q3 25 | $80.3M | — | ||
| Q2 25 | $78.9M | — | ||
| Q1 25 | $80.2M | $486.5M | ||
| Q4 24 | $77.8M | $526.3M | ||
| Q3 24 | $72.6M | $554.6M | ||
| Q2 24 | $64.6M | $582.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $570.0K | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $570.0K | — | ||
| Q4 25 | $2.6M | — | ||
| Q3 25 | $881.0K | — | ||
| Q2 25 | $5.0M | — | ||
| Q1 25 | $1.4M | $-38.5M | ||
| Q4 24 | $3.8M | $-31.6M | ||
| Q3 24 | $2.8M | $-24.3M | ||
| Q2 24 | $1.7M | $39.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-975.0K | — | ||
| Q3 25 | $543.0K | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $527.0K | $-39.7M | ||
| Q4 24 | $2.1M | $-32.2M | ||
| Q3 24 | $2.8M | $-24.9M | ||
| Q2 24 | $1.7M | $38.8M |
| Q1 26 | — | — | ||
| Q4 25 | -6.6% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 4.0% | -192.9% | ||
| Q4 24 | 15.8% | -86.2% | ||
| Q3 24 | 22.9% | -127.3% | ||
| Q2 24 | 15.9% | 41.0% |
| Q1 26 | — | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 6.9% | 5.6% | ||
| Q4 24 | 13.2% | 1.7% | ||
| Q3 24 | 0.5% | 3.3% | ||
| Q2 24 | 0.3% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.19× | — | ||
| Q3 25 | 16.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.16× | -27.94× | ||
| Q3 24 | 1.25× | — | ||
| Q2 24 | — | 0.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
TRDA
Segment breakdown not available.
